Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT04164576

Study of the Pathogenicity and Humoral Immune Response Induced by BK Virus in Lung Transplant Recipients

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
120 (estimated)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

BK virus (BKV) is a ubiquitous virus that infects more than 80% of the population. In case of immunosuppression, BKV can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow transplant recipients. The disruption of the balance between BKV replication and immune control is considered the key element in the development of these pathologies. During lung transplantation, patients undergo intense immunosuppression that favors the reactivation of persistent viruses such as EBV, CMV and probably BKV. Although the data on EBV and CMV reactivation are very clear and allow optimal management, the prevalence of BKV replication and its clinical impact in lung transplant recipients remains unknown at this time. The aim of this study is to know the incidence and clinical impact of BKV replication in lung transplant recipients. Moreover, the results will help to better understand the interaction between the virus and his host, with a focus on the humoral and cellular immune response against BKV. The results could possibly enable to define predictive markers of BKV replication and of its evolution.

Conditions

Interventions

TypeNameDescription
GENETICTransplant patientsStudy the specific immunity against Polyomavirus

Timeline

Start date
2020-01-01
Primary completion
2020-01-01
Completion
2027-06-01
First posted
2019-11-15
Last updated
2019-11-15

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04164576. Inclusion in this directory is not an endorsement.